Efficacy and Safety of ABBV-154 in Patients With Moderately-to-Severely Active Crohn’s Disease: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial
Crohn's & Colitis 360 · 09.04.2026
DOI: 10.1093/crocol/otag014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Crohn's & Colitis 360, online erschienen am 09.04.2026. Verfasst von Walter Reinisch und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Medical University of Vienna, Vienna, Austria. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
ABBV-154 is an antibody-drug conjugate of adalimumab and a proprietary glucocorticoid receptor modulator. This phase 2 b randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of ABBV-154 versus placebo in patients with moderately to severely active Crohn’s disease who had inadequate response to or were intolerant of prior biologic therapy.
Methods
Patients were randomized 1:1:1:1:1 to ABBV-154 induction groups: 150 mg IV at week 0, then 80 mg SC at week 2 and every other week (EOW); 300 mg IV at week 0, then 230 mg SC at week 2 and EOW; 600 mg IV at week 0, then 530 mg SC at week 2 and EOW; 600 mg IV at week 0, then 530 mg SC at weeks 4 and 8, and placebo at weeks 2, 6, and 10; or placebo. The primary endpoint was achievement of endoscopic response per SES-CD by central review at week 12. Adverse events were monitored throughout.
Results
Of 265 planned patients, 106 were randomized and treated until completion, discontinuation, or early study termination by the sponsor. At week 12, greater proportions of patients treated with ABBV-154 achieved endoscopic response versus placebo (7.1%, 33.3%, 28.6%, and 27.3% across the induction groups versus 0%; data reported as observed). Adverse events were comparable across all ABBV-154 groups and slightly higher than placebo through week 12.
Conclusions
ABBV-154 was well tolerated and demonstrated proof-of-concept for efficacy in patients with moderately to severely active Crohn’s disease. Results should be interpreted with caution due to early study termination.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Medical University of Vienna, Vienna, Austria.
- Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Université de Lorraine, Vandœuvre-lès-Nancy, France.
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC, Canada.
- Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
- Department of Internal Medicine-Gastroenterology, German Red Cross Hospital Berlin, Berlin, Germany.
- AbbVie Inc., North Chicago, IL, United States.
ORCID-Profile: Walter Reinisch, Laurent Peyrin-Biroulet, Geert D'Haens, Jaclyn K Anderson, Izabella Messina, Ronilda D'Cunha, Edouard Louis
Zitieren
APA
Reinisch, W., Peyrin-Biroulet, L., D'Haens, G., Sturm, A., Anderson, J. K., Messina, I., Arikan, D., Zimmerman-Bennett, A., Parmentier, J., Feng, T., D'Cunha, R., Lazar, A., & Louis, E. (2026). Efficacy and Safety of ABBV-154 in Patients With Moderately-to-Severely Active Crohn’s Disease: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial. Crohn's & Colitis 360. https://doi.org/10.1093/crocol/otag014
Vancouver
Reinisch W, Peyrin-Biroulet L, D'Haens G, Sturm A, Anderson JK, Messina I, et al. Efficacy and Safety of ABBV-154 in Patients With Moderately-to-Severely Active Crohn’s Disease: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial. Crohn's & Colitis 360. 2026. doi:10.1093/crocol/otag014
BibTeX
@article{Reinisch2026,
author = {Reinisch, Walter and Peyrin-Biroulet, Laurent and D'Haens, Geert and Sturm, Andreas and Anderson, Jaclyn K and Messina, Izabella and Arikan, Dilek and Zimmerman-Bennett, Alissa and Parmentier, Julie and Feng, Tian and D'Cunha, Ronilda and Lazar, Andreas and Louis, Edouard},
title = {Efficacy and Safety of ABBV-154 in Patients With Moderately-to-Severely Active Crohn’s Disease: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial},
journal = {Crohn's & Colitis 360},
year = {2026},
doi = {10.1093/crocol/otag014}
}
EUVIMED